Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
about
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaA novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclastsBortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyA randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myelomaSpecific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.Initial treatment of transplant-ineligible patients in multiple myeloma.Defining and treating high-risk multiple myeloma.Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.
P2860
Q28296718-B0D25FD6-11FA-4F4A-AB2D-EC296F1514B4Q28543087-50E421EB-7562-4254-953F-267DA0E989DDQ33696008-315F54AC-215E-4E15-AB5E-94749CE2AA69Q34149903-28E43E9E-5FFA-4304-924F-7C778D691DB6Q36258034-B4C2F9D1-746C-4606-8680-20B066ED82BDQ36595290-7AD5AE67-F392-48B0-BF55-8CC9CBB8BFB9Q37033951-5622E743-88AC-4ADD-8FA4-7177B4C6BDFFQ37037265-0A6990A2-7B1D-4103-9D4A-66CF5345264DQ37275721-E4296ABB-E29A-421D-A68A-011BCA336F7EQ38000078-A2AE10D0-9246-4DFD-8786-3B12E49CE117Q38031989-627996F7-8A90-4443-98D3-5F5EE448135FQ38155425-AEA19683-99F5-47BF-AD8B-46D34B57D252Q38168891-DB5F8CA1-DCDE-4B9D-A48E-BCECA1207CA8Q38564926-CC489A94-E96D-41CF-8B7B-E7E42FACFD92Q38645307-E1921C56-5BD0-4860-9DF8-9FF565967E7DQ39177792-129FCFF2-43C9-44C9-B273-8A381CC2F8DEQ39303373-205DEE02-33F3-4499-A544-3819CA19AD75Q39524467-66C31E89-4732-4CED-ACC5-3EF3D2DD4B03Q41177165-0A079E04-16BB-4E88-8961-A496C91AF459Q42365345-74748FF1-DDE4-4E87-99AD-C6D73BB9771EQ48129787-E7FA4385-E800-46A3-BA17-F10AB1979F92Q53179212-FE54510F-7521-43BD-A373-35A2351A2DB8Q55119916-EDEBFE55-0498-480F-BBD5-880125DB3515
P2860
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Outcome according to cytogenet ...... zomib followed by maintenance.
@en
Outcome according to cytogenet ...... zomib followed by maintenance.
@nl
type
label
Outcome according to cytogenet ...... zomib followed by maintenance.
@en
Outcome according to cytogenet ...... zomib followed by maintenance.
@nl
prefLabel
Outcome according to cytogenet ...... zomib followed by maintenance.
@en
Outcome according to cytogenet ...... zomib followed by maintenance.
@nl
P2093
P50
P1433
P1476
Outcome according to cytogenet ...... zomib followed by maintenance.
@en
P2093
Alejandro Martín
Ana-Isabel Teruel
Anna Sureda
Bruno Paiva
Enrique Bengoechea
Felipe de Arriba
Francisco-Javier Peñalver
Jesús F San Miguel
Joan Bargay
Joan Bladé
P304
P356
10.1182/BLOOD-2011-04-345801
P407
P577
2011-09-06T00:00:00Z